NUCLEAR MEDICINE REVIEW is a distinguished journal in the field of radiology, nuclear medicine, and imaging, published by VIA MEDICA in Poland. Since its transition to an open access format in 1999, this journal has been dedicated to promoting the dissemination of knowledge and research findings across a global audience. With a focus on innovative approaches and advancements in nuclear medicine, it aims to serve as a key resource for researchers, professionals, and students who are working to further the understanding of nuclear imaging and its applications. In 2023, the journal was classified in the Q3 category within Radiology, Nuclear Medicine and Imaging, and Q4 in the broader category of Medicine (miscellaneous), highlighting its growing reputation in the academic community. As of the latest assessments, the journal has been ranked #235 out of 333 in its field according to Scopus metrics, reflecting its commitment to excellence and the relevance of its published works. The NUCLEAR MEDICINE REVIEW is a pivotal platform for those engaged in cutting-edge research, providing insights that drive the evolution of medical imaging and therapeutic techniques.

The European Journal of Radiology, published by Elsevier Ireland Ltd, is a premier peer-reviewed journal in the fields of radiology, nuclear medicine, and imaging. Established in 1981, it has carved a significant niche within the academic community, showcasing innovative research that enhances medical imaging practices and improves patient care. With an impressive ranking in the Q1 category for both Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging in 2023, the journal is recognized globally for its commitment to advancing scientific knowledge and improving imaging methodologies. The journal's Scopus ranking of #60/333, placing it in the 82nd percentile, underlines its reputation for high-quality research and scholarly contributions. While traditionally a subscription-based journal, it continually evolves to meet the demands of the academic landscape, aiming to bridge the gap between research and clinical practice. Researchers, healthcare professionals, and students alike can benefit from exploring its extensive archives and current publications, which are curated to foster education and innovation in the medical imaging domain.

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

CLINICAL NUCLEAR MEDICINE is a premier journal dedicated to the field of nuclear medicine, published by Lippincott Williams & Wilkins. With a history of excellence since its inception in 1978, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to deepen their understanding of this rapidly evolving discipline. The journal holds a commendable Q2 ranking in both Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging, reflecting its significant impact on advancing clinical practices and research. While currently not offered as an open-access publication, CLINICAL NUCLEAR MEDICINE ensures rigorous peer review and high-quality publications, contributing to the broad dissemination of cutting-edge studies and reviews. With its comprehensive scope encompassing both diagnostic and therapeutic nuclear medicine applications, researchers around the globe turn to this journal to stay informed and inspire innovations in patient care for the years leading up to 2024 and beyond.

The European Journal of Nuclear Medicine and Molecular Imaging is a prestigious, peer-reviewed journal published by Springer, dedicated to advancing the field of nuclear medicine and molecular imaging. With an impressive impact factor and ranked in the Q1 category for both Medicine and Radiology, Nuclear Medicine and Imaging, this journal is a pivotal platform for researchers and practitioners to disseminate significant findings from 1996 to the present, reflecting the evolution of the field. The journal boasts a notable Scopus rank, standing at #8 out of 333 in its category, placing it in the top 3% of published works, which highlights its critical importance in shaping contemporary practices and research innovations. Although it does not offer an open-access model, the journal provides various access options to ensure that important research is accessible to professionals, students, and academics alike. Through rigorous peer review and a commitment to high-quality publication, the European Journal of Nuclear Medicine and Molecular Imaging plays an essential role in the advancement of nuclear medicine, contributing to better diagnostic and therapeutic outcomes globally.

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Imaging. Since its inception in 1977, this journal has been dedicated to advancing the understanding and application of computer-assisted tomography, emphasizing innovative research and clinical practices that enhance diagnostic imaging techniques. With an impact factor reflective of its rigorous scholarship and relevance—ranking in the Q3 category—the journal serves as an essential platform for contributors and readers alike, navigating the challenges and opportunities within a rapidly evolving field. Researchers, professionals, and students are encouraged to engage with the rich repository of articles that cover emerging technologies, clinical applications, and theoretical advancements, collectively fostering a deeper comprehension of imaging sciences. Although not currently designated as an open-access journal, it continues to enhance discourse in the community from its headquarters in Philadelphia, PA, maintaining a commitment to the highest standards of academic excellence.

Welcome to the Iranian Journal of Radiology, a pivotal platform dedicated to advancing the field of radiology, nuclear medicine, and medical imaging. Published by BRIEFLAND, this journal aims to disseminate high-quality original research, reviews, and clinical studies that contribute substantially to the global scientific community. Established in 2008 and spanning until 2024, the journal provides an essential archive of knowledge in a rapidly evolving discipline. Although it currently holds a Q4 quartile ranking in the 2023 Scopus metrics, it serves as an important resource for both emerging and established researchers looking to submit their work. Located in the Netherlands, the journal is committed to open dialogue and collaboration amongst professionals in the field, reflecting its accessibility and relevance to both practitioners and academics. With its continued growth and commitment to quality, the Iranian Journal of Radiology is poised to enhance understanding and innovation in diagnostic imaging.

Current Radiopharmaceuticals, published by Bentham Science Publishers Ltd, is an esteemed journal dedicated to advancing the field of radiopharmaceuticals. With an ISSN of 1874-4710 and an E-ISSN of 1874-4729, this journal has been a significant platform for researchers since its inception in 2009, and will continue to contribute to the literature until at least 2024. Current Radiopharmaceuticals is recognized for its impactful contributions, holding a record of Q3 in Pharmacology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023, illustrating its vital role in these domains. The journal aims to provide a comprehensive overview of the latest techniques, applications, and innovations within the field of radiopharmaceutical science, catering to a diverse audience of researchers, professionals, and students. Despite its significant contributions, the journal remains committed to enriching the academic community with high-quality, peer-reviewed articles that can be accessed worldwide, reflecting a dedication to open dialogue and knowledge dissemination in radiopharmaceutical research.

European Journal of Hybrid Imaging, published by SpringerNature, stands as a pivotal platform for scholarly discourse in the rapidly evolving fields of hybrid imaging technologies and methodologies. Since its inception in 2017, this open access journal has significantly contributed to the interdisciplinary interface of biophysics, computer science, molecular medicine, and radiology. With its current standing in the Q2 and Q3 quartiles across various categories, it provides valuable insights and research outputs pertinent to both academic and clinical practitioners. The journal's rigorous peer-review process ensures the highest standards of scholarly integrity, while its open access format promotes global accessibility and encourages collaborative research efforts. Covering a diverse range of topics pertinent to hybrid imaging, the journal serves as an essential resource for researchers, professionals, and students alike, fostering innovation and knowledge exchange within the scientific community.

NUKLEARMEDIZIN-NUCLEAR MEDICINE is a prestigious journal published by Georg Thieme Verlag KG, focusing on pivotal advancements in the fields of Nuclear Medicine, Radiology, and Imaging. Established in 1959, this journal has served as a critical platform for disseminating innovative research, reviews, and clinical guidelines until its anticipated convergence in 2024. With an ISSN of 0029-5566 and an E-ISSN of 2567-6407, NUKLEARMEDIZIN is acknowledged in the academic community as a Q3 category journal within Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging as of 2023, highlighting its ongoing contribution to the interdisciplinary dialogue in healthcare. Although the journal does not currently offer open access, it remains accessible to professionals and students through various academic databases, ensuring that cutting-edge knowledge in this growing field is shared widely. Researchers interested in the latest methods and technologies in Nuclear Medicine will find NUKLEARMEDIZIN a valuable resource for enhancing their work and understanding the complexities of modern imaging modalities.